Over a decade since the first clinical trials began, long-term follow-up data have affirmed CAR T-cells’ ability to induce durable remissions in certain patients. However, the therapy also faces challenges, as not all treated cancers respond equally well and toxicity remains a concern. Ongoing research aims to optimize various aspects of CAR T-cell treatment to improve outcomes on a broader scale.
![The Promise of CAR T-Cells: Progress and Challenges in Cancer Immunotherapy](https://darkdrug.com/wp-content/uploads/2024/06/AdobeStock_522303148-scaled-e1717449595542-1080x675.jpeg)